Literature DB >> 17070241

Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.

Axel Häcker1, Stefan Jeschke, Karl Leeb, Kurt Prammer, Josef Ziegerhofer, Wolfgang Sega, Werner Langsteger, Guenter Janetschek.   

Abstract

PURPOSE: Accurate detection of lymph node metastases in prostate cancer has important implications for prognosis and approach to treatment. We investigated whether preoperative [18F]fluorocholine combined in-line positron emission tomography-computerized tomography and intraoperative laparoscopic radioisotope guided sentinel pelvic lymph node dissection can detect pelvic lymph node metastases in patients with clinically localized prostate cancer as reliably as extended pelvic lymph node dissection.
MATERIALS AND METHODS: A total of 20 patients (mean age 63.9 +/- 6.7 years, range 52 to 75) with clinically localized prostate cancer, prostate specific antigen greater than 10 ng/ml, and/or a Gleason score sum of 7 or greater and negative bone scan were enrolled in the study. [18F]fluorocholine combined in-line positron emission tomography-computerized tomography was performed before surgery. Sentinel pelvic lymph node dissection preceded extended pelvic lymph node dissection including the area of the obturator fossa, external iliac artery/vein and internal iliac artery/vein up to the bifurcation of the common iliac artery. Laparoscopic radical prostatectomy was performed afterward.
RESULTS: In 10 of the 20 patients (50%) lymph node metastases were detected, and were exclusively found outside the obturator fossa in 62%. These metastases would not have been identified with standard lymph node dissection of the obturator fossa only. [18F]fluorocholine combined in-line positron emission tomography-computerized tomography was true positive in 1, false-positive in 2, false-negative in 9 and true negative in 8 patients. The largest lymph node metastasis not seen with [18F]fluorocholine combined in-line positron emission tomography-computerized tomography was 8 mm. Laparoscopic sentinel guided lymph node dissection revealed lymph node metastases in 8 of 10 patients. In the other 2 patients sentinel lymph node dissection was not conclusive. In 1 patient normal nodal tissue was completely replaced by cancer and, therefore, there was no tracer uptake in the involved pelvic sidewall/node, and the other patient had no tracer activity at all in the involved pelvic sidewall. Extended pelvic lymph node dissection missed 1 lymph node metastasis (2 mm diameter near pudendal artery) which was detected by sentinel pelvic lymph node dissection only.
CONCLUSIONS: Extended pelvic lymph node dissection reveals a higher number of lymph node metastases as described for obturator fossa dissection only. [18F]fluorocholine combined in-line positron emission tomography-computerized tomography is not useful in searching for occult lymph node metastases in clinically localized prostate cancer. Sentinel guided pelvic lymph node dissection allows the detection of even small lymph node metastases. The accuracy of sentinel pelvic lymph node dissection is comparable to that of extended pelvic lymph node dissection when the limitations of the method are taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070241     DOI: 10.1016/j.juro.2006.07.037

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  42 in total

1.  PET/CT imaging of recurrent prostate cancer.

Authors:  B Scher; M Seitz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

2.  Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure.

Authors:  Isabelle Brenot-Rossi; Dominique Rossi; Benjamin Esterni; Serge Brunelle; Guillaume Chuto; Cyrille Bastide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-09       Impact factor: 9.236

Review 3.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

Review 4.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

Review 5.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

Review 6.  Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Authors:  Reza Vali; Wolfgang Loidl; Christian Pirich; Werner Langesteger; Mohsen Beheshti
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

Review 7.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

Review 8.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

9.  [Imaging diagnostics of advanced prostate cancer].

Authors:  A Kretschmer; M Seitz; A Graser; C G Stief; D Tilki
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

Review 10.  [Sentinel node dissection in prostate cancer: current status].

Authors:  D Weckermann; G Holl; T Wagner; R Harzmann
Journal:  Urologe A       Date:  2007-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.